文献速递老年精神心境障碍

阿司匹林对老年抑郁长期管理的影响:双盲随机安慰剂对照试验

Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial.
PubMed 文献 · Mol Psychiatry · 2021-01-27

ASPREE-D 是 ASPREE 的子研究,纳入 1879 名基线抑郁的澳大利亚与美国社区老年人,随机接受每日 100 mg 阿司匹林或安慰剂,中位随访 4.7 年。阿司匹林组抑郁评分显著升高(0.6;95% CI 0.2~0.9;p=0.001),生活质量心理健康组分显著降低(-0.7;95% CI -1.4~-0.1;p=0.029),效应量小至极小。研究未显示阿司匹林对老年抑郁长期病程有益,并提示对已有抑郁症状者可能存在不良影响。

要点

  • 每日100 mg阿司匹林未改善老年抑郁长期病程,抑郁评分反而升高。
  • 阿司匹林组生活质量心理健康组分显著下降,效应量小至极小。
  • 效应在随访第一年更明显并持续全程,提示对已有抑郁症状者可能不利。

核心结论

  • 在社区居住的老年抑郁人群中,每日100 mg阿司匹林未显示对抑郁长期病程的获益,反而与抑郁评分升高相关。

研究设计与样本

  • ASPREE-D 是 ASPREE 的子研究,为多中心、基于人群、双盲、安慰剂对照试验,纳入 1879 名基线抑郁的澳大利亚与美国老年人。
  • 参与者随机接受每日 100 mg 阿司匹林或安慰剂,中位随访 4.7 年。
  • 抑郁症状每年使用经验证的流行病学研究中心抑郁量表自评简版评估。

主要发现

  • 阿司匹林组较安慰剂组抑郁评分显著升高(0.6;95% CI 0.2~0.9;χ2(1)=10.37;p=0.001)。
  • 阿司匹林组较安慰剂组生活质量量表心理健康组分显著降低(-0.7;95% CI -1.4~-0.1;χ2(1)=4.74;p=0.029)。
  • 上述效应在随访第一年更明显并持续全程,但效应量为小至极小。

关键数值与推荐

  • 阿司匹林剂量为每日 100 mg,对照为安慰剂,中位随访 4.7 年。
  • 抑郁评估工具为流行病学研究中心抑郁量表自评简版,每年评估一次。

临床怎么用

  • 对已有抑郁症状的老年患者,不应期望阿司匹林改善抑郁长期病程。
  • 处方阿司匹林时应关注抑郁症状与心理健康相关生活质量的可能变化。

局限性

  • 原文摘要未报告样本代表性、失访率、依从性及亚组分析等局限信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Late-life depression is common and often inadequately managed using existing therapies. Depression is also associated with increased markers of inflammation, suggesting a potential role for anti-inflammatory agents. ASPREE-D is a sub-study of ASPREE, a large multi-centre, population-based, double-blind, placebo-controlled trial of aspirin vs placebo in older Australian and American adults (median follow-up: 4.7 years) of whom 1879 were depressed at baseline. Participants were given 100 mg daily dose of aspirin or placebo. Depressive symptoms were assessed annually using the validated, self-rated short version of the Center for Epidemiological Studies Depression scale. There was a significant increase in depressive scores (0.6; 95% CI 0.2 to 0.9; χ2 (1) = 10.37; p = 0.001) and a decreased score in the mental health component of a quality of life scale (-0.7; 95% CI -1.4 to -0.1; χ2 (1) = 4.74; p = 0.029) in the aspirin group compared to the placebo group. These effects were greater in the first year of follow-up and persisted throughout the study, albeit with small to very small effect sizes. This study failed to demonstrate any benefit of aspirin in the long-term course of depression in this community-dwelling sample of older adults over a 5-year period, and identified an adverse effect of aspirin in the course of depression in those with pre-existing depressive symptoms.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Berk M, Agustini B, Woods RL, et al. Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial. Mol Psychiatry. 2021. PMID: 33504953. doi:10.1038/s41380-021-01020-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。